Skip to main content
. Author manuscript; available in PMC: 2016 May 12.
Published in final edited form as: Oncogene. 2012 Apr 9;32(7):861–871. doi: 10.1038/onc.2012.105

Figure 2.

Figure 2

Inhibiting mTOR signalling reduces primary tumor burden and lung metastasis in PyMT/Tsc2+/+ and PyMT/Tsc2+/− mice. (a) Pulmonary metastatic burden in PyMT/Tsc2+/+ and PyMT/Tsc2+/− mice. Pulmonary metastases were counted in all lobes and normalized to the lung area; n = 8; **P = 0.05; ***P<0.01. (b) Immunohistochemical analysis of TSC2 and p-S6 expression levels in lungs from PyMT/Tsc2+/+ and PyMT/Tsc2+/− mice. Bar, 0.2 mm. (c) Tumor weight in PyMT/Tsc2+/+ and PyMT/Tsc2+/− mice treated with RAP (n = 8) or vehicle (n = 8). *P<0.001 (d) Quantitation of TUNEL-positive cells from pulmonary metastasis and primary tumors from PyMT/Tsc2+/+ and PyMT/Tsc2+/− mice treated with vehicle or RAP. A total of three tumors were analyzed. *P<0.005; error bars denote s.e.m. (e) Quantitation of Ki-67-positive cells from pulmonary metastasis and primary tumors from PyMT/Tsc2+/+ and PyMT/Tsc2+/− mice treated with vehicle or RAP. A total of three tumors were analyzed. Error bars denote s.e.m.